Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.65 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125441 | 1.00 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL219711 | 0.98 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Iodide SCHEMBL221293 | 0.98 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Bromide SCHEMBL221648 | 0.98 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydroxyamphetamine SCHEMBL7041719 | 0.83 | TAAR1 (0.66) | SIGMAR1TAAR1SLC18A2SLC6A4 | |
| SCHEMBL30624762 | 0.81 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL21243273 | 0.81 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL2958028 | 0.80 | SLC6A4 (0.63) | SIGMAR1TAAR1SLC6A4CYP3A4CYP2D6 | |
| Methamphetamine SCHEMBL18227057 | 0.80 | SIGMAR1 (0.91) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL42615 | 0.79 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155687-A1 | METHODS OF TREATMENT USING AN AMPHETAMINE PRODRUG | SHIRE PHARMACEUTICALS INC. (US) | 2020-05-21 | — | — | US | disclosed |
| WO-2019199724-A1 | SALTS OF AMPHETAMINE-HOMOARGININE CONJUGATE PRODRUG | SHIRE PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019136224-A1 | AMPHETAMINE-GUANFACINE COMBINATIONS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20140194524-A1 | Methods for Treating Alzheimer's Disease | COGNITION PHARMACEUTICALS, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140171510-A1 | HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | SHIRE LLC (KY) | 2014-06-19 | — | — | US | disclosed |
| EP-2739140-A1 | HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | Shire LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20130231395-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | COGNITION PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2013019187-A1 | HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120142785-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | COGNITION PHARMACEUTICALS LLC (US) | 2012-06-07 | — | — | US | disclosed |
| CN-1826105-B | Use of amphetamine composition in producing medicine for treating cognitive impairment | SENTION INC | 2010-09-08 | — | — | CN | disclosed |
| US-20060111448-A1 | Methods for treating cognitive impairment in humans with multiple sclerosis | SENTION, INC., PROVIDENCE, RI | 2006-05-25 | — | — | US | disclosed |
| EP-1635851-A2 | METHODS FOR TREATING COGNITIVE IMPAIRMENT AND IMPROVING COGNITION | Sention, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050059743-A1 | Treatment with particular enantiomers levo-amphetamine or levo-methamphetamine without adverse side effects | SENTION, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005000203-A2 | METHODS FOR TREATING COGNITIVE IMPAIRMENT AND IMPROVING COGNITION | SENTION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6828351-B2 | Use of specified enantiomers of amphetamine, levo-amphetamine for enhancing and/or restoring long-term memory function and performance | SENTION, INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1420768-A2 | METHODS AND COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION | Sention, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030232890-A1 | Methods for treating an impairment in memory consolidation | SENTION, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030119884-A1 | Methods and compositions for regulating memory consolidation | PANMEDIX, INC. | 2003-06-26 | — | — | US | disclosed |
| US-20020115725-A1 | Methods and compositions for regulating memory consolidation | PRIESTLEY, KATHERINE (GB) | 2002-08-22 | — | — | US | disclosed |
| WO-2002039998-A2 | METHODS AND COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION | SENTION, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171510-A1 | HOMOARGININE PRODRUGS AND/OR CONJUGATES OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | COMT, PNMT, HNMT | SIGMAR1 893/4885TAAR1 162/4885SLC18A2 19/4885 |
| US-20060111448-A1 | Methods for treating cognitive impairment in humans with multiple sclerosis | COMT, PNMT, CHAT | SIGMAR1 1616/4885TAAR1 86/4885SLC18A2 101/4885 |
| US-20140194524-A1 | Methods for Treating Alzheimer's Disease | CHAT, ACHE, PNMT | SIGMAR1 1971/4885TAAR1 74/4885SLC18A2 17/4885 |
| US-20030232890-A1 | Methods for treating an impairment in memory consolidation | PNMT, CHAT, DOT1L | SIGMAR1 333/4885TAAR1 20/4885SLC18A2 90/4885 |
| US-20050059743-A1 | Treatment with particular enantiomers levo-amphetamine or levo-methamphetamine without adverse side effects | COMT, PNMT, MAPT | SIGMAR1 663/4885TAAR1 39/4885SLC18A2 191/4885 |
| US-20200155687-A1 | METHODS OF TREATMENT USING AN AMPHETAMINE PRODRUG | PNMT, HNMT, COMT | SIGMAR1 1147/4885TAAR1 114/4885SLC18A2 12/4885 |
| US-20130231395-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | CHAT, ACHE, PNMT | SIGMAR1 1971/4885TAAR1 74/4885SLC18A2 17/4885 |
| US-20030119884-A1 | Methods and compositions for regulating memory consolidation | BDNF, CHAT, DCX | SIGMAR1 2170/4885TAAR1 944/4885SLC18A2 308/4885 |
| US-20020115725-A1 | Methods and compositions for regulating memory consolidation | BDNF, CHAT, GAP43 | SIGMAR1 2161/4885TAAR1 491/4885SLC18A2 322/4885 |
| US-20120142785-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | ACHE, PNMT, MAPT | SIGMAR1 1925/4885TAAR1 156/4885SLC18A2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.